The acceptability of antidepressant treatment in people living with HIV in Malawi: A patient perspective.

• DOI: 10.17615/a7wt-3148
• Publication Date: 2023-01-02
• Authors: Kazione Kulisewa; Caroline E. Minnick; Melissa A. Stockton; Bradley N. Gaynes; Mina C. Hosseinipour; Steven Mphonda; Griffin Sansbury; Michael M. Udedi; Brian W. Pence
• Keywords: Malawi; Depression; Amitriptyline; hiv; Pilot Projects; HIV Infections; Article; Antidepressive Agents; 3. Good health; antidepressants; acceptability; Fluoxetine; depression; Humans; Public aspects of medicine; RA1-1270; qualitative research

Depression is common among people living with HIV (PLWH). Measurement-based care models that measure depression severity and antidepressant side effects, and use an algorithm to guide antidepressant prescription by non-specialized health workers represent an evidence-based treatment for severe depression in sub-Saharan Africa. We conducted in-depth interviews from June to December 2018 with eleven patients enrolled in Project SOAR-Mental Health, a pilot project integrating depression treatment into HIV care in Malawi. Patients treated with amitriptyline or fluoxetine participated in interviews exploring antidepressant acceptability through patient knowledge, side effect severity, pill burden, adherence, perceived efficacy, and tolerability. Patients described a lack of detailed antidepressant education from their providers. Variable, typically self-limiting side effects were reported from both amitriptyline and fluoxetine. While most side effects were mild, three patients reported functional impairment. Patients reported high adherence, though the additional pill burden was a challenge. Most patients found the antidepressants efficacious, tolerable, beneficial and acceptable. Although patient psychoeducation is notably lacking as a facet of clinical management, antidepressant prescription by primary care providers appears acceptable for comorbid severe depression in PLWH initiating HIV care in sub-Saharan Africa. Health workers should be mindful of dosing to minimise side effects and considerate of the additional pill burden. Trial registration: ClinicalTrials.gov ID [NCT03555669]. Retrospectively registered on 13 June 2018.